Rafi S. Ahmed - Nanotechnology

Author Information

Rafi Ahmed is a distinguished researcher affiliated with the Emory Vaccine Center at Emory University School of Medicine, located in Atlanta, GA. His work primarily focuses on immunology, with significant contributions to understanding immune responses to viral infections, particularly SARS-CoV-2 and other viruses.

Research Contributions

Rafi Ahmed has made substantial contributions to the field of immunology. His recent research has focused on the immune response to SARS-CoV-2, including the impact of pre-existing immunity on the effectiveness of vaccines, the longevity of antibody responses, and the immune response in patients with various cancers and other conditions. His work is pivotal in understanding the durability and breadth of immune protection, which is crucial for developing effective vaccines and treatments. Notably, his studies also extend to other viral infections, such as ebolaviruses, showcasing his broad expertise in virology and immunology.

Aliases

Rafi Ahmed is also known by several aliases, including R. Ahmed, R Ahmed, and Rafi S. Ahmed. These variations may appear in different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	95,059
h-index	150
Paper Count	667

Publications:

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

DOI: 10.1016/j.xcrm.2022.100603

Year: 2022

Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses

DOI: 10.1016/j.cell.2022.02.023

Year: 2022

Persistence of Virus-Specific Antibody after Depletion of Memory B Cells

DOI: 10.1128/jvi.00026-22

Year: 2022

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.

DOI: 10.1200/JCO.22.00088

Year: 2022

In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles

DOI: 10.1126/sciadv.abm7950

Year: 2022

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.

DOI: 10.1200/JCO.21.02257

Year: 2022

Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.

DOI: 10.1101/2022.01.03.22268599

Year: 2022

Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant

DOI: 10.1101/2021.02.02.21250799

Year: 2021

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

DOI: 10.1101/2021.04.19.21255739

Year: 2021

Response to Whole-Lung Low-Dose Radiation Therapy (LD-RT) Predicts Freedom from Intubation in Patients Receiving Dexamethasone and/or Remdesevir for COVID-19-Related Acute Respiratory Distress Syndrome (ARDS)

DOI: 10.1101/2021.02.10.21251242

Year: 2021

How is Nanotechnology Applied in Surveillance?

What is the SCGSR Program?

How Does Nanotechnology Enhance Wearable Electronics?

How Does Nanotechnology Enhance CPU Performance?

What are Hybrid Materials?

How Does Optical Switching Work?

What is a Bonded Wafer?

Why is Decoherence a Problem in Nanotechnology?

How are Nanoceramic Coatings Applied?

What are the Challenges in Working with Molecular Materials?

Partnered Content Networks

Relevant Topics